Court Ruling: Injunction on Release of Zyprexa Documents
A federal Judge of the Eastern District (Brooklyn) issued a ruling upholding a seal on documents that contain evidence linking Zyprexa, Eli Lilly's antipsychotic drug to diabetes
A federal Judge of the Eastern District (Brooklyn) issued a ruling upholding a seal on documents that contain evidence linking Zyprexa, Eli Lilly's antipsychotic drug to diabetes
Two Press Briefings are planned to demonstrate the multiple flaws in FDA's methodology and to provide credible science-based information.
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
A major 17-year follow up study published in the British Journal of Psychiatry [1] found a 2.84 times (95% CI 2.06–3.90) increased risk of mortality in people with schizophrenia compared to those not so diagnosed, and with each addition of a neuroleptic (antipsychotic) drug, the risk increased another 2.50.
By denigrading all non-chemical interventions, by focusing narrowly on drugs and drugs alone, psychiatry has signed away its profession status.
IOM committee members were highly critical of FDA’s advisory panels that regularly “recommend” approval without analyzing the safety data.
"It’s not a question of just knowing the risks and it’s not a question of labeling against risk. The question is how do you change behavior?"
Pharmaceutical News reports that the FDA has issued warnings about diet pills from Brazil marketed as dietary supplements, that contain Prozac and Librium.
In what appears to be a re-run of the Katrina rescue disaster–The New York Times front page report provides yet another example of mindless and heartless shot gun public polices that are being tested on a vulnerable population of citizens: